Daratumumab as successful initial therapy for AL amyloidosis with nerve involvement

Click to increase image sizeClick to decrease image size

Author contributions

S.D. wrote the first draft and approved the final version of the manuscript; M.A.G., A.D., S.K.K., and S.A.P. revised the manuscript critically and approved the final version of the manuscript. E.D. mentored the manuscript writing and approved the final version of the manuscript.

Disclosure statement

Shweta Deshpande: None; Morie A. Gertz: Consultancy (Millenium) and honoraria (Celgene, Millenium, Onyx, Novartis, Smith Kline, Prothena, Ionis). Angela Dispenzieri: Research funding (Celgene, Millennium, Pfizer, and Janssen), Travel grant (Pfizer). Shaji Kumar: Consultancy (Celgene, Millennium, Onyx, Janssen, and BMS); and research funding (Celgene, Millennium, Novartis, Onyx AbbVie, Janssen, and BMS). Sameer A. Parikh: Research funding has been provided to the institution from Pharmacyclics, MorphoSys, Janssen, AstraZeneca, TG Therapeutics, and Ascentage Pharma for clinical studies in which Sameer A.Parikh is a principal investigator. Sameer A.Parikh has also participated in Advisory Board meetings of Pharmacyclics, AstraZeneca, Genentech, Gilead, and AbbVie (he was not personally compensated for his participation). Eli Muchtar: None.